Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Glycoprotein Receptor Binding Domain (SARS-CoV-2 Spike RBD)
- Target
- SARS-CoV-2 Spike RBD
- Molecular classification
- Glycoprotein, Viral Protein, Receptor Binding Domain
01
Overview
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike glycoprotein’s receptor binding domain (RBD) is a surface-exposed domain within the S1 subunit of the trimeric spike protein. It is responsible for binding to the human ACE2 receptor, enabling viral entry into host cells. The RBD is a primary target for neutralizing antibodies and is highly immunogenic, making it a principal antigen in vaccine design and a target for monoclonal antibody therapies and small-molecule inhibitors.
- Other names
- SARS-CoV-2 RBDSpike RBDRBD
02
Mechanism of action
Binding to ACE2 receptor to block viral entry. Neutralization via antibody binding.
03
Biological functions
Receptor bindingViral entryImmune recognitionMembrane fusion
04
Disease associations
COVID-19Infection
05
Safety considerations
Antibody-dependent enhancement (ADE)Evasion by viral mutationsOff-target effects of inhibitors
06
Interacting drugs
Monoclonal Antibodies (e.g., CR3022)
2 more in the full profile.
07
Biomarkers
RBD-specific antibody titersNeutralizing antibody titers
Beyond the preview
Go deeper on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Glycoprotein Receptor Binding Domain (SARS-CoV-2 Spike RBD).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Glycoprotein Receptor Binding Domain (SARS-CoV-2 Spike RBD).